TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC September 3, 1999
TCL Archive Blochs Plan To Fund National Network Of “Cancer Survivor Parks” In Every City August 3, 1990
